Efficacy and safety of zoledronic acid in the treatment of glucocorticoid-induced osteoporosis

Ege Can Serefoglu1
Zafer Tandogdu2
1Kiziltepe Hospital, Department of Urology, Mardin, Turkey; 2Taksim Teaching Hospital, Department of Urology, Istanbul, Turkey

Abstract: Glucocorticoids are essential in treating many disorders and they are widely used in spite of their negative impact on the skeletal system. As bisphosphonates reduce bone resorption through their action on osteoclasts, they play an important role in management of glucocorticoid-induced osteoporosis. Unlike other bisphosphonates, zoledronic acid is given by intravenous infusion and it has a potential advantage of increasing the compliance and adherence of patients when it is given 5 mg once a year. However, this treatment modality seems to be associated with more adverse events than oral administrations, and further studies with longer follow-up periods must be conducted to determine the safety and cost-effectiveness of long-term treatment with zoledronic acid.

Keywords: bisphosphonates, glucocorticoids, osteoporosis, zoledronic acid

Introduction
Glucocorticoids (GCs) are steroidal stress hormones which have many different biological functions.1,2 Through binding to GC receptors, they exert most of their effects, such as regulating tissue differentiation during development, controlling intermediary metabolism and coordinating the adjustment of physiological processes in response to stress.3–5 Because of these effects, synthetic GCs have been developed which are widely used in the treatment of allergic, inflammatory, lymphoproliferative disorders, and autoimmune diseases.6–10 However, such a treatment is not without shortcomings: GCs exert a negative impact on the skeletal system as they result in a rapid, early phase of bone loss which is followed by a more chronic and progressive phase due to excessive bone resorption, in which finally the bone mass declines because of impaired bone formation.11 The administration of GCs is the most frequent secondary cause of osteoporosis and it has been demonstrated that more than one third of individuals treated with GCs for 5 to 10 years will have an osteoporotic fracture.12,13

The purpose of this review is to discuss the pathophysiology of glucocorticoid-induced osteoporosis (GIO) and the efficacy and safety of zoledronic acid in the treatment of this disorder.

Pathophysiology of glucocorticoid-induced osteoporosis
Although it is estimated that, 30%–50% of patients using long-term GCs experience relevant bone loss, the exact prevalence of GIO is still unknown.14,15 The pathophysiology of GIO is complicated, as GCs may exert their effects on the skeletal system in many ways. In the beginning GCs cause an increase in bone resorption, however the most important effect of GCs is their action in decreasing bone formation by decreasing...
osteoblast proliferation and inhibiting osteoblasts from producing new bone.\textsuperscript{16,17} In addition, osteocyte apoptosis can be detected in GIO, which results in microarchitectural deterioration, as these cells are considered to determine bone strength independent of bone mineral density (BMD).\textsuperscript{18} On the other hand, GCs also have systemic effects on bone metabolism as they have a negative effect on calcium homeostasis by decreasing absorption of calcium from the intestine and increasing calcium loss in the urine, as a result of defective vitamin D metabolism. This leads to secondary hyperparathyroidism, which results in increased bone resorption.\textsuperscript{15,16} Moreover, GCs affect bone metabolism indirectly by reducing levels of sex hormones as a result of suppressed pituitary gonadotrophin secretion.\textsuperscript{16}

Treatment of glucocorticoid-induced osteoporosis and bisphosphonates

As GIO is an important problem due to the increased risk of fracture, preventive measures are suggested in order to stabilize or increase the BMD in such patients, and consequently reduce the risk of fracture. It has been demonstrated that regular BMD assessment, and management of osteoporosis is suboptimal in patients using long-term GCs, despite the fact that screening and treatment rates have increased in recent years.\textsuperscript{19} In an attempt to increase the rates of screening and treatment of osteoporosis in long-term GC users, Curtis et al employed an online continuing medical education program for physicians who prescribed long-term GC therapy.\textsuperscript{20} Although the final results of this study revealed that the education provided did not yield any advantage when compared to the control group, a greater amount of education may be beneficial and the mode of education may affect the outcome.

Calcium and vitamin D supplementation, increasing BMD, and preventing high cortisol levels, are the main strategies in treating GIO. Moreover, numerous clinical trials have now demonstrated that bisphosphonates are highly effective at limiting bone loss in patients with GIO.\textsuperscript{21} Furthermore, in GC-treated patients at high risk of fracture, bisphosphonate therapy has proved to be cost-effective.\textsuperscript{22} Thus, nowadays bisphosphonates are considered to be the gold standard for the prevention and treatment of GIO, along with sufficient intakes of calcium and vitamin D as they increase BMD, and reduce vertebral fracture risk in patients beginning or continuing GC treatment.\textsuperscript{23–28} The nitrogen-containing bisphosphonates act by inhibiting farnesyl diphosphate (FPP) synthase, a key enzyme of the mevalonate pathway, which is critical to the production of cholesterol, other sterols, and isoprenoid lipids. The inhibition of osteoclasts by the nitrogen-containing bisphosphonates is very likely mediated by their action on the FPP synthase, which leads to protracted apoptosis of these giant cells.\textsuperscript{29,30}

Although daily oral bisphosphonate therapy with alendronate or risedronate is effective for treatment of GIO, compliance and adherence with daily and weekly therapy has been shown to be suboptimal.\textsuperscript{31–35} This finding is important, as an association between poor adherence and increased fracture risk has been demonstrated in women with postmenopausal osteoporosis who were treated with oral bisphosphonate.\textsuperscript{36} Therefore, studies were conducted in order to search for an alternative treatment regime which would increase the compliance and adherence of patients with GIO.\textsuperscript{37}

Zoledronic acid in the treatment of glucocorticoid-induced osteoporosis

Like other bisphosphonates, zoledronic acid binds to the calcium phosphate bone mineral hydroxyapatite, predominantly localizing at regions of high bone turnover.\textsuperscript{38,39} Additionally, the affinity of zoledronic acid for hydroxyapatite was shown to be higher than that of other bisphosphonates in an \textit{in vitro} study.\textsuperscript{38} In osteoporosis, zoledronic acid inhibits osteoclast-mediated resorption, therefore reducing bone turnover.

Zoledronic acid, which is available as an intravenous formulation, is approved for the treatment of osteoporosis in postmenopausal women and, more recently, in men at increased risk of fracture, and in patients in Europe with a recent low-trauma hip fracture.\textsuperscript{40} Intravenous zoledronic acid 5 mg, administered via infusion, is the first once-yearly treatment approved for these indications.\textsuperscript{41–44}

The efficacy of zoledronic acid for preventing and treating GIO was studied by HORIZON (Health Outcomes and Reduced Incidence with Zoledronic Acid Once) investigators in a large international study, where patients were randomized to receive either intravenous 5 mg zoledronic acid or oral 5 mg risedronate.\textsuperscript{37} This study demonstrated that one 5 mg infusion of zoledronic acid annually increases bone mineral density of the lumbar spine and femoral neck, trochanter, and total hip more than the oral 5 mg risedronate daily, in patients who had recently started GCs (prevention group n:288) and in those who had been already taking them (treatment group n:545).\textsuperscript{37} The patients were followed for 12 months and BMD was measured at 6th and 12th months. The primary endpoint of the study was the percentage change from baseline in BMD, while changes in bone turnover biomarker concentrations were measured as secondary end-points. Evaluation of this study indicated that the increase in BMD at 6 months was significantly higher with zoledronic acid than it was with risedronate (Figure 1). It has
also been shown that inhibition of the bone turnover markers was faster and more substantial in patients receiving zoledronic acid. Unfortunately, this study was not able to detect differences in fracture risk.\textsuperscript{32} However, various studies have demonstrated that once-yearly administration of zoledronic acid 5 mg is effective in preventing fractures.\textsuperscript{45–47} Bearing this in mind, we may speculate that annual administration of 5 mg zoledronic acid will be efficacious in preventing bone fractures. However this speculation requires further studies to verify it.

Severe adverse effects associated with the use of intravenous bisphosphonates are uncommon, however approximately 10% to 30% of patients receiving their first nitrogen-containing bisphosphonate infusion will experience an acute phase reaction within the first 3 days of treatment. This is most commonly characterized by transient pyrexia with associated myalgias, arthralgias, headaches, and influenza-like symptoms.\textsuperscript{37} This acute phase response is believed to be the result of proinflammatory cytokine production by peripheral blood T cells.\textsuperscript{48} The reactions are typically self-limited and resolve completely within 24 to 48 hours. In addition to the administration of adequate fluid, NSAIDs or acetaminophen may be useful supportive treatments. The frequency of pyrexia within the first days of treatment was 15% in a study where no co-drug was used during the administration of zoledronic acid, however in a study where NSAIDs or paracetamol was administered with zoledronic acid the rate was 8.7% (Figure 1).\textsuperscript{37,45} Fortunately, the frequency of these reactions is rare in subsequent infusions of nitrogen-containing bisphosphonates.\textsuperscript{37,49}

Ocular complications, nephrotoxicity, and/or electrolyte abnormalities such as hypocalcemia, hypophosphatemia, and hypomagnesemia are also reported.\textsuperscript{50} The most frequent observed ocular complication is nonspecific conjunctivitis, which is usually self-limited.\textsuperscript{50} On the other hand uveitis can also be seen after the administration of zoledronic acid and this requires medical treatment.\textsuperscript{51} The physician administering intravenous bisphosphonates should be alert for such situations where patients present with ocular pain, itching, or decrease in vision, and in such cases they should promptly direct the patient to be examined by an ophthalmologist.\textsuperscript{50}

Previous studies have proved that the effect of risdro- nates on renal functions is comparable with placebo even in patients with impaired renal functions.\textsuperscript{52} It is well known that all intravenous bisphosphonates have the potential to affect renal functions, especially in patients whose renal function is compromised.\textsuperscript{53} However the findings of the HORIZON study did not demonstrate a higher rate of renal impairment in patients receiving zoledronic acid treatment than in patients in the risedronate arm.\textsuperscript{53} When we take the previously-mentioned studies’ results into consideration it may be further speculated that zoledronic acid may be comparable with placebo with respect to renal complications.

Electrolyte abnormalities can also be a problem in zoledronic acid treatment. In a multicenter review hypocalcemia was reported in 35% of patients after zoledronic acid infusion whereas symptomatic hypocalcemia requiring treatment was observed in 8% of patients despite prophylactic measures.\textsuperscript{54}

Bisphosphonates have been linked to osteonecrosis of the jaw which can be prevented with pretherapy dental care.\textsuperscript{55} It has been shown that prolongation of bisphosphonate treatment increases the frequency of osteonecrosis of the jaw.\textsuperscript{56} The management of this situation is a matter for debate and depends on the stage at which it is diagnosed.

In the HORIZON-PFT (Health Outcomes and Reduced Incidence with Zoledronic Acid Once Pivotal Fracture Trial), where patients were treated annually with intravenous zoledronic acid, a statistically-significant increase in the incidence of serious atrial fibrillation (defined as events resulting in hospitalization, or disability, or judged to be life-threatening) was noted.\textsuperscript{52} The etiology of this electrophysiologic abnormality is not clarified yet. Unfortunately, we have limited data regarding other bisphosphonate preparations which may have the potential to produce similar rates of atrial fibrillation. One large population-based case-control study suggested a correlation between alendronate administration and a slightly-increased incidence of atrial fibrillation.\textsuperscript{57} Previous studies have proved that the effect of risdro- nates on renal functions is comparable with placebo even in patients with impaired renal functions.\textsuperscript{52} It is well known that all intravenous bisphosphonates have the potential to affect renal functions, especially in patients whose renal function is compromised.\textsuperscript{53} However the findings of the HORIZON study did not demonstrate a higher rate of renal impairment in patients receiving zoledronic acid treatment than in patients in the risedronate arm.\textsuperscript{53} When we take the previously-mentioned studies’ results into consideration it may be further speculated that zoledronic acid may be comparable with placebo with respect to renal complications.

Electrolyte abnormalities can also be a problem in zoledronic acid treatment. In a multicenter review hypocalcemia was reported in 35% of patients after zoledronic acid infusion whereas symptomatic hypocalcemia requiring treatment was observed in 8% of patients despite prophylactic measures.\textsuperscript{54}

Bisphosphonates have been linked to osteonecrosis of the jaw which can be prevented with pretherapy dental care.\textsuperscript{55} It has been shown that prolongation of bisphosphonate treatment increases the frequency of osteonecrosis of the jaw.\textsuperscript{56} The management of this situation is a matter for debate and depends on the stage at which it is diagnosed.

In the HORIZON-PFT (Health Outcomes and Reduced Incidence with Zoledronic Acid Once Pivotal Fracture Trial), where patients were treated annually with intravenous zoledronic acid, a statistically-significant increase in the incidence of serious atrial fibrillation (defined as events resulting in hospitalization, or disability, or judged to be life-threatening) was noted.\textsuperscript{52} The etiology of this electrophysiologic abnormality is not clarified yet. Unfortunately, we have limited data regarding other bisphosphonate preparations which may have the potential to produce similar rates of atrial fibrillation. One large population-based case-control study suggested a correlation between alendronate administration and a slightly-increased incidence of atrial fibrillation.
fibrillation, whereas another population-based case-control study showed no evidence of an increased risk of atrial fibrillation or flutter with alendronate use.\textsuperscript{57,58} On the other hand, no increase was detected in the rate of atrial fibrillation seen in patients received IV zoledronic acid after a hip fracture (the HORIZON Recurrent Fracture Trial).\textsuperscript{15,59} Apparently, more studies examining the potential relationship between bisphosphonate use and atrial fibrillation are required.

**Conclusion**

Since GCs are essential in treating many disorders, physicians should consider their negative effects on skeletal health, and they must be aware of GIO prior to administering these drugs. As bisphosphonates reduce bone resorption through their actions on osteoclasts, they play an important role in management of GIO. However awareness rates are much below those expected. Future studies focusing on improving the understanding of GIO and its management should be conducted, as it may be beneficial to increase the awareness of physicians about GIO and its treatment options through rigorous education programs.

Zoledronic acid, which is given by intravenous infusion, has a potential advantage of increasing the compliance and adherence of patients when it is given 5 mg, once a year. Zoledronic acid is effective in preventing and treating GIO, with a overall high safety and tolerability rate, and a low rate of serious adverse events. Future studies concentrating on the long-term effects and cost-effectiveness would be beneficial. In addition, research focusing on new targets such as anabolic drugs which stimulate bone formation by acting on osteoblasts and osteocytes could lead to a more compelling rationale for use than bisphosphonates.

**Disclosures**

The authors report no conflicts of interest in this work.

**References**

1. Kino T. Tissue glucocorticoid sensitivity: beyond stochastic regulation on the diverse actions of glucocorticoids. *Horm Metab Res*. 2007;39(6):420–424.

2. Viegas LR, Hoijman E, Beato M, Pecci A. Mechanisms involved in tissue-specific apoptosis regulated by glucocorticoids. *J Steroid Biochem Mol Biol*. 2008;109(3–5):273–278.

3. Baxter JD, Rousseau GG. Glucocorticoid Hormone Action: an overview. *Monogr Endocrinol*. 1979;(12):1–24.

4. Cole TJ, Blendy JA, Monaghan AP, et al. Targeted disruption of the glucocorticoid receptor gene blocks adrenergic chromaffin cell development and severely retards lung maturation. *Genes Dev*. 1995;9(13):1608–1621.

5. Berger S, Bleich M, Schmid W, et al. Mineralocorticoid receptor knockout mice: pathophysiology of Na+ metabolism. *Proc Natl Acad Sci U S A*. 1998;95(16):9424–9429.

6. McCabe BF. Autoimmune sensorineural hearing loss. *Ann Otol Rhinol Laryngol*. 1979;88(5 Pt 1):585–589.

7. Dodson KM, Sismanis A. Intratympanic perfusion for the treatment of tinnitus. *Otolaryngol Clin North Am*. 2004;37(5):991–1000.

8. Dodson KM, Woodson E, Sismanis A. Intratympanic steroid perfusion for the treatment of Ménière’s disease: a retrospective study. *Ear Nose Throat J*. 2004;83(6):394–398.

9. Tait AS, Butts CL, Sternberg EM. The role of glucocorticoids and progestins in inflammatory, autoimmune, and infectious disease. *J Leukoc Biol*. 2008;84(4):924–931.

10. Trune DR, Kempton JB, Harrison AR, Wobig JL. Glucocorticoid impact on cochlear function and systemic side effects in autoimmune C3.MRL-Faslpr and normal C3H/HeJ mice. *Hear Res*. 2007;226(1–2):209–217.

11. Canalis E, Bilezkinian JP, Angeli A, Giustina A. Perspectives on glucocorticoid-induced osteoporosis. *Bone*. 2004;34(4):593–598.

12. Baltzan MA, Suissa S, Bauer DC, Cummings SR. Hip fractures attributable to corticosteroid use. *Lancet*. 1999;353(9161):1327.

13. Center JR, Nguyen TV, Schneider D, Sambrook PN, Eisman JA. Mortality after all major types of osteoporotic fracture in men and women: an observational study. *Lancet*. 1999;353(9165):1707.

14. Cooper C, Coupland C, Mitchell M. Rheumatoid arthritis, corticosteroid therapy and hip fracture. *Ann Rheum Dis*. 1995;54(1):49–52.

15. Reid IR. Glucocorticoid osteoporosis—mechanisms and management. *Eur J Endocrinol*. 1997;137(3):209–217.

16. McIlwain HH. Glucocorticoid-induced osteoporosis: pathogenesis, diagnosis, and management. *Prev Med*. 2003;36(2):243–249.

17. Delany AM, Dong Y, Canalis E. Mechanisms of glucocorticoid action in bone cells. *J Cell Biochem*. 1994;56(3):295–302.

18. van Staa TP. The pathogenesis, epidemiology and management of glucocorticoid-induced osteoporosis. *Calcif Tissue Int*. 2006;79(3):129–137.

19. Curtis JR, Westfall AO, Allison JJ, et al. Longitudinal patterns in the prevention of osteoporosis in glucocorticoid treated patients. *Arthritis Rheum*. 2005;52(8):1485–1494.

20. Curtis JR, Westfall AO, Allison J, et al. Challenges in improving the quality of osteoporosis care for long-term glucocorticoid users: a prospective randomized trial. *Arch Intern Med*. 2007;167(6):591–596.

21. de Nijs RN, Jacobs JW, Lems WF, et al. Alendronate or alfacalcidol in glucocorticoid-induced osteoporosis. *N Engl J Med*. 2006;355(7):675–684.

22. van Staa TP, Geusens P, Zhang B, Leufkens HG, Boonen A, Cooper C. Individual fracture risk and the cost-effectiveness of bisphosphonates in patients using oral glucocorticoids. *Rheumatology* (Oxford). 2007;46(3):460–466.

23. Cohen S, Levy RM, Keller M, et al. Risedronate therapy prevents corticosteroid-induced bone loss: a twelve-month, multicenter, randomized, double-blind, placebo-controlled, parallel-group study. *Arthritis Rheum*. 1999;42(11):2309–2318.

24. Reid DM, Hughes RA, Laan RF, et al. Efficacy and safety of daily risedronate therapy in corticosteroid-induced osteoporosis in men and women: a randomized trial. European Corticosteroid-Induced Osteoporosis Treatment Study. *Eur J Endocrinol*. 2000;155(6):1006–1013.

25. Saag KG, Emkey R, Schnitzer TJ, et al. Alendronate for the prevention and treatment of glucocorticoid-induced osteoporosis. *Bone*. 2003;34(4):593–598.

26. Compston JE. Emerging consensus on prevention and treatment of glucocorticoid-induced osteoporosis. *Curr Rheumatol Rep*. 2007;9(1):78–84.

27. Compston J. US and UK guidelines for glucocorticoid-induced osteoporosis: similarities and differences. *Curr Rheumatol Rep*. 2004;6(1):66–69.

28. Adler RA, Hochberg MC. Suggested guidelines for evaluation and treatment of glucocorticoid-induced osteoporosis for the Department of Veterans Affairs. *Arch Intern Med*. 2003;163(21):2619–2624.
29. Weinstein RS, Roberson PK, Manolagas SC. Giant osteoclast and long-term oral bisphosphonate therapy. N Engl J Med. 2009;360(1):53–62.
30. Roelofs AJ, Thompson K, Gordon S, Rogers MJ. Molecular mechanisms of action of bisphosphonates: current status. Clin Cancer Res. 2006;12(20 Pt 2):6222–6230.
31. Tanveytovon T, Stiff PP. Management of the adverse effects associated with intravenous bisphosphonates. Ann Oncol. 2006;17(6):897–907.
32. Hamilton B, McCoy K, Taggart H. Tolerability and compliance with bisphosphonates in clinical practice. Osteoporos Int. 2003;14(3):259–262.
33. Cramer JA, Lynch NO, Gaudin AF, Walker M, Cowell W. The effect of dosing frequency on compliance and persistence with bisphosphonate therapy in postmenopausal women: a comparison of studies in the United States, the United Kingdom, and France. Clin Ther. 2006;28(10):1686–1694.
34. Cramer JA, Gold DT, Silverman SL, Lewicki EM. A systematic review of persistence and compliance with bisphosphonates for osteoporosis. Osteoporos Int. 2007;18(8):1023–1031.
35. Seeman E, Compston J, Adachi J, et al. Non-compliance: the Achilles’ heel of anti-fracture efficacy. Osteoporos Int. 2007;18(6):711–719.
36. Siris ES, Harris ST, Rosen CJ, et al. Adherence to bisphosphonate therapy and fracture rates in osteoporotic women: relationship to vertebral and nonvertebral fractures from 2 US claims databases. Mayo Clin Proc. 2006;81(8):1013–1022.
37. Reid DM, Devogelaer JP, Saag K, et al. Zoledronic acid and risedronate in the prevention and treatment of glucocorticoid-induced osteoporosis (HORIZON): a multicentre, double-blind, double-dummy, randomised controlled trial. Lancet. 2009;373(9671):1253–1263.
38. Nancollas GH, Tang R, Phipps RJ, et al. Novel insights into actions of bisphosphonates on bone: differences in interactions with hydroxyapatite. Bone. 2006;38(5):617–627.
39. Dunford JE, Thompson K, Coxon FP, et al. Structure-activity relationships for inhibition of farnesyl diphosphate synthase in vitro and inhibition of bone resorption in vivo by nitrogen-containing bisphosphonates. J Clin Pharmacol Exp Ther. 2001;296(2):235–242.
40. European Medicines Agency. Aclasta: summary of product characteristics [online]. April 14, 2010. Available from: http://www.emea.europa.eu/ md/human/docs/EPAR/aclasta/aclosta.htm. Accessed on April 26, 2010.
41. Food and Drug Administration. Reclast® (zoledronic acid) injection: US prescribing information [online]. Available from: http://www.accessdata.fda.gov/drugsatfda_docs/label/2008/021817s001lbl.pdf.
42. Black DM, Delmas PD, Eastell R, et al. Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med. 2007;356(18):1809–1822.
43. McClung M, Recker R, Miller P, et al. Intravenous zoledronic acid 5 mg in the treatment of postmenopausal women with low bone density previously treated with alendronate. Bone. 2007;41(1):122–128.
44. Chen T, Berenson J, Vescio R, et al. Pharmacokinetics and pharmaco-dynamics of zoledronic acid in cancer patients with bone metastases. J Clin Pharmacol. 2002;42(11):1228–1236.
45. Lyles KW, Colon-Emeric CS, Magaziner JS, et al. Zoledronic acid and clinical fractures and mortality after hip fracture. N Engl J Med. 2007;357(18):1799–1809.
46. Boonen S, Black MD, Colon-Emeric SC, et al. Efficacy and safety of a once yearly intravenous zoledronic acid 5 mg for fracture prevention in elderly postmenopausal women with osteoporosis aged 75 and older. JAGS. 2010;58:292–299.
47. Eriksson EF, Lyles KW, Colon-Emeric CS, et al. Antifracture efficacy and reduction of mortality in relation to timing of the first dose of zoledronic acid after hip fracture. J Bone Miner Res. 2009;Vol 24(7):1308–1313.
48. Hewitt RE, Lissina A, Green AE, Slay ES, Price DA, Sewell AK. The bisphosphonate acute phase response: rapid and copious production of proinflammatory cytokines by peripheral blood gd T cells in response to aminobisphosphonates is inhibited by statins. Clin Exp Immunol. 2005;139(1):101–111.
49. Conte PF, Giannarelli V. Safety of intravenous and oral bisphosphonates and compliance with dosing regimen. Oncologist. Vol 9, Suppl 4, 2004.
50. Fraunfelder FW, Fraunfelder FR, Jensvold B. Scleritis and other ocular side effects associated with pamidronate disodium. Am J Ophthalmol. 2001;135:219–222.
51. Colucci A, Modorati G, Miserocchi E, et al. Anterior uveitis complicating zoledronic acid infusion. Ocul Immunol Inflamm. 2009;17(4):267–268.
52. Miller PD, Roux C, Boonen S, et al. Safety and efficacy of risedronate in patients with age related reduced renal functions as estimated by the Cockcroft and Gault method: a pooled analysis of nine clinical trials. J Bone Miner Res. 2005;20:2105–2115.
53. Lawansky S, Komaroff E, Cavanaugh PF, et al. Relationship between age, renal function and bone mineral density in the US population. Osteoporos Int. 2003;14:570–576.
54. Chennuru S, Koduri J, Baumann MA. Risk factors for symptomatic hypocalcaemia complicating treatment with zoledronic acid. Intern Med J. 2008;38(6):635–637.
55. Marx RE, Sawatari Y, Fortin M, Broumond V. Bisphosphonate-induced exposed bone (osteonecrosis/osteoporosis) of the jaws: risk factors, recognition, prevention, and treatment. J Oral Maxillofac Surg. 2005;63(11):1567–1575.
56. Khosla S, Burr D, Cauley J. Bisphosphonate-associated osteonecrosis of the jaw: report of a task force of the American society for bone and mineral research. J Bone Miner Res. 2007;22(10):1479–1491.
57. Heckbert SR, Li G, Cummings SR, Smith NL, Paity BM. Use of alendronate and risk of incident atrial fibrillation in women. Arch Intern Med. 2008;168(8):826–831.
58. Sorensen HT, Christensen S, Mehnert F, et al. Use of bisphosphonates and reduced risk of fracture and death among women and risk of atrial fibrillation and flutter: population based case-control study. BMJ. 2000;336(7648):813–816.
59. Karam R, Cramm J, McClung M. Yearly zoledronic acid in postmenopausal osteoporosis. N Engl J Med. 2007;357(7):712–713.